Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.38 |
| ▸ | TNKS | O95271 | 6/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 2/20 | 0.34 |
| ▸ | ERG | P11308 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314870 | 0.84 | TNKS2 (0.38) | TNKS2TNKSTGFBR1TACR3ERG | |
| SCHEMBL314869 | 0.84 | TNKS2 (0.38) | TNKS2TNKSTGFBR1TACR3ERG | |
| SCHEMBL314041 | 0.84 | TNKS2 (0.40) | BRD4TNKS2TNKSTGFBR1MAPK14 | |
| SCHEMBL314042 | 0.84 | TNKS2 (0.40) | BRD4TNKS2TNKSTGFBR1MAPK14 | |
| SCHEMBL314043 | 0.84 | TNKS2 (0.40) | BRD4TNKS2TNKSTGFBR1MAPK14 | |
| SCHEMBL314626 | 0.84 | TNKS2 (0.38) | TNKS2TNKSTGFBR1TACR3ERG | |
| SCHEMBL313824 | 0.80 | TNKS2 (0.40) | TNKS2TNKSTGFBR1MAPK14THRB | |
| SCHEMBL314758 | 0.80 | TNKS2 (0.40) | TNKS2TNKSTGFBR1MAPK14THRB | |
| SCHEMBL314350 | 0.80 | TNKS2 (0.40) | TNKS2TNKSTGFBR1MAPK14THRB | |
| SCHEMBL12654553 | 0.79 | TNKS2 (0.39) | TNKS2TNKSTGFBR1TACR3ERG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| EP-1966211-B1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | BRD4 808/4885TNKS2 630/4885TNKS 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.